ZA200503791B - Dermastic thickened ointment - Google Patents
Dermastic thickened ointment Download PDFInfo
- Publication number
- ZA200503791B ZA200503791B ZA200503791A ZA200503791A ZA200503791B ZA 200503791 B ZA200503791 B ZA 200503791B ZA 200503791 A ZA200503791 A ZA 200503791A ZA 200503791 A ZA200503791 A ZA 200503791A ZA 200503791 B ZA200503791 B ZA 200503791B
- Authority
- ZA
- South Africa
- Prior art keywords
- solid stick
- amount
- present
- composition
- solid
- Prior art date
Links
- 239000002674 ointment Substances 0.000 title description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 111
- 239000000203 mixture Substances 0.000 claims description 103
- 239000007787 solid Substances 0.000 claims description 58
- 230000000699 topical effect Effects 0.000 claims description 46
- 239000003246 corticosteroid Substances 0.000 claims description 38
- 235000019271 petrolatum Nutrition 0.000 claims description 37
- 235000013772 propylene glycol Nutrition 0.000 claims description 37
- 229960004063 propylene glycol Drugs 0.000 claims description 37
- 239000004264 Petrolatum Substances 0.000 claims description 33
- 229940066842 petrolatum Drugs 0.000 claims description 33
- 239000001993 wax Substances 0.000 claims description 27
- 230000001681 protective effect Effects 0.000 claims description 21
- 239000003995 emulsifying agent Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 claims description 13
- 229960004703 clobetasol propionate Drugs 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 238000004806 packaging method and process Methods 0.000 claims description 5
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 229960005078 sorbitan sesquioleate Drugs 0.000 claims description 4
- 229940070710 valerate Drugs 0.000 claims description 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000012188 paraffin wax Substances 0.000 claims description 3
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims description 2
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 claims description 2
- HHJIUUAMYGBVSD-YTFFSALGSA-N Diflucortolone valerate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)COC(=O)CCCC)[C@@]2(C)C[C@@H]1O HHJIUUAMYGBVSD-YTFFSALGSA-N 0.000 claims description 2
- 229950000210 beclometasone dipropionate Drugs 0.000 claims description 2
- 229960001102 betamethasone dipropionate Drugs 0.000 claims description 2
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 claims description 2
- 229960004311 betamethasone valerate Drugs 0.000 claims description 2
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 claims description 2
- BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 claims description 2
- 229960003970 diflucortolone valerate Drugs 0.000 claims description 2
- 229960002714 fluticasone Drugs 0.000 claims description 2
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 2
- 150000002334 glycols Chemical class 0.000 claims description 2
- 229960001524 hydrocortisone butyrate Drugs 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 229960002744 mometasone furoate Drugs 0.000 claims description 2
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims description 2
- 229960002117 triamcinolone acetonide Drugs 0.000 claims description 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 2
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229960002383 halcinonide Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 23
- 229960001334 corticosteroids Drugs 0.000 description 13
- 150000003431 steroids Chemical class 0.000 description 10
- 230000035515 penetration Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 206010047139 Vasoconstriction Diseases 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 230000025033 vasoconstriction Effects 0.000 description 6
- 229940001017 temovate Drugs 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- -1 alkali metal salts Chemical class 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000036074 healthy skin Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 229960002537 betamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 229940068372 acetyl salicylate Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- XCJYREBRNVKWGJ-UHFFFAOYSA-N copper(II) phthalocyanine Chemical compound [Cu+2].C12=CC=CC=C2C(N=C2[N-]C(C3=CC=CC=C32)=N2)=NC1=NC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 XCJYREBRNVKWGJ-UHFFFAOYSA-N 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940031569 diisopropyl sebacate Drugs 0.000 description 1
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/292,756 US20040091539A1 (en) | 2002-11-13 | 2002-11-13 | Dermastick thickened ointment |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200503791B true ZA200503791B (en) | 2008-01-30 |
Family
ID=32229522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200503791A ZA200503791B (en) | 2002-11-13 | 2003-11-12 | Dermastic thickened ointment |
Country Status (11)
Country | Link |
---|---|
US (2) | US20040091539A1 (zh) |
EP (1) | EP1560562A2 (zh) |
JP (2) | JP5419317B2 (zh) |
CN (1) | CN1738601A (zh) |
AU (1) | AU2003292494A1 (zh) |
BR (1) | BR0316153A (zh) |
CA (1) | CA2504807A1 (zh) |
MX (1) | MXPA05005020A (zh) |
RU (1) | RU2328271C2 (zh) |
WO (1) | WO2004043331A2 (zh) |
ZA (1) | ZA200503791B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2597525A1 (en) * | 2005-02-17 | 2006-08-24 | Senju Pharmaceutical Co., Ltd. | Solid ophthalmic drug for external use |
US9694100B2 (en) | 2009-12-08 | 2017-07-04 | Smith & Nephew, Inc. | Enzymatic wound debriding compositions with enhanced enzymatic activity |
US8685381B2 (en) | 2010-10-23 | 2014-04-01 | Joel Schlessinger | Topical base and active agent-containing compositions, and methods for improving and treating skin |
US8968755B2 (en) | 2010-10-23 | 2015-03-03 | Joel Schlessinger | Topical base and active agent-containing compositions, and methods for improving and treating skin |
DE102012207989A1 (de) * | 2012-05-14 | 2013-11-14 | Beiersdorf Ag | Aromatisierte Lippenbutter |
CN105434181B (zh) * | 2015-12-30 | 2019-04-23 | 广州市科能化妆品科研有限公司 | 一种双层不含水的护肤组合物及其制备方法 |
WO2019189756A1 (ja) * | 2018-03-30 | 2019-10-03 | ロート製薬株式会社 | 外用油性固形組成物 |
WO2020158879A1 (ja) * | 2019-01-31 | 2020-08-06 | 久光製薬株式会社 | 貼付剤 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1483220A (en) * | 1922-05-24 | 1924-02-12 | Theodore W Foster & Bro Co | Container for toilet preparations |
US4070462A (en) * | 1976-10-26 | 1978-01-24 | Schering Corporation | Steroid ointment |
US4229432A (en) * | 1978-04-19 | 1980-10-21 | Bristol-Myers Company | Antiperspirant stick composition |
US4299828A (en) * | 1979-05-31 | 1981-11-10 | E. R. Squibb & Sons, Inc. | Corticosteroid stick formulations |
US4396615A (en) * | 1981-06-24 | 1983-08-02 | Duke University | Method of treating androgen-related disorders |
US4514383A (en) * | 1982-05-05 | 1985-04-30 | Johnson & Johnson Baby Products Company | Sunscreen compositions containing vinylogous amides |
US5110809A (en) * | 1988-03-21 | 1992-05-05 | Bristol-Myers Squibb Company | Antifungal gel formulations |
US4883792A (en) * | 1989-01-17 | 1989-11-28 | Peter Timmins | Steroid cream formulation |
FR2679467B1 (fr) * | 1991-07-26 | 1993-10-15 | Oreal | Dispersion solide d'au moins un alcool polyhydrique dans un milieu anhydre et procede de preparation. |
US5543148A (en) * | 1994-07-12 | 1996-08-06 | Combe, Incorporated | Stick delivery system for topical application of a treatment agent |
JPH0853368A (ja) * | 1994-08-09 | 1996-02-27 | Kyoto Yakuhin Kogyo Kk | 軟膏製剤 |
JP3485375B2 (ja) * | 1995-02-17 | 2004-01-13 | 株式会社資生堂 | 皮膚外用剤 |
IT1287114B1 (it) * | 1996-10-31 | 1998-08-04 | Recordati Chem Pharm | Composizioni farmaceutiche antierpetiche per applicatori topici, contenenti aciclovir |
US6503488B1 (en) * | 1998-11-17 | 2003-01-07 | Tend Skin International, Inc. | Topical compositions including deodorant compositions |
GB9902227D0 (en) * | 1999-02-01 | 1999-03-24 | Cipla Limited | Pharmaceutical composition for topical administration |
JP2001172125A (ja) * | 1999-12-17 | 2001-06-26 | Yoshinori Nagumo | 皮膚外用剤 |
US6464994B1 (en) * | 2000-01-19 | 2002-10-15 | Mentis Technologies, L.C. | Diaper dermatitis preventative medication and a method for making and using same |
US6403123B1 (en) * | 2000-09-19 | 2002-06-11 | Eugene J. Van Scott | Method for topical treatment of anthralin-responsive dermatological disorders |
-
2002
- 2002-11-13 US US10/292,756 patent/US20040091539A1/en not_active Abandoned
-
2003
- 2003-11-12 RU RU2005118085/15A patent/RU2328271C2/ru not_active IP Right Cessation
- 2003-11-12 CN CNA2003801087572A patent/CN1738601A/zh active Pending
- 2003-11-12 JP JP2004551114A patent/JP5419317B2/ja not_active Expired - Fee Related
- 2003-11-12 AU AU2003292494A patent/AU2003292494A1/en not_active Abandoned
- 2003-11-12 MX MXPA05005020A patent/MXPA05005020A/es active IP Right Grant
- 2003-11-12 ZA ZA200503791A patent/ZA200503791B/en unknown
- 2003-11-12 CA CA002504807A patent/CA2504807A1/en not_active Abandoned
- 2003-11-12 EP EP03768076A patent/EP1560562A2/en not_active Withdrawn
- 2003-11-12 BR BR0316153-6A patent/BR0316153A/pt not_active IP Right Cessation
- 2003-11-12 WO PCT/IB2003/006381 patent/WO2004043331A2/en active Application Filing
-
2007
- 2007-06-28 US US11/824,319 patent/US20080089939A1/en not_active Abandoned
-
2011
- 2011-05-12 JP JP2011107278A patent/JP2011241211A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2004043331A3 (en) | 2004-09-30 |
JP5419317B2 (ja) | 2014-02-19 |
JP2006515570A (ja) | 2006-06-01 |
EP1560562A2 (en) | 2005-08-10 |
AU2003292494A8 (en) | 2004-06-03 |
CN1738601A (zh) | 2006-02-22 |
BR0316153A (pt) | 2005-09-27 |
CA2504807A1 (en) | 2004-05-27 |
US20080089939A1 (en) | 2008-04-17 |
WO2004043331A2 (en) | 2004-05-27 |
RU2328271C2 (ru) | 2008-07-10 |
AU2003292494A1 (en) | 2004-06-03 |
MXPA05005020A (es) | 2005-08-03 |
US20040091539A1 (en) | 2004-05-13 |
JP2011241211A (ja) | 2011-12-01 |
RU2005118085A (ru) | 2006-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080089939A1 (en) | Dermastick thickened ointment | |
US10940205B2 (en) | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | |
AU744712B2 (en) | Activated vitamin D3 emulsion-type lotions | |
RU2271810C2 (ru) | Композиции местного применения, содержащие, по меньшей мере, один витамин d или один аналог витамина d и, по меньшей мере, один кортикостероид | |
US4082881A (en) | Topical and other type pharmaceutical formulations containing isosorbide carrier | |
US5292499A (en) | Method of preparing medical aerosol formulations including drug dissolved in reverse micelles | |
US20140050673A1 (en) | Oil-Based Foamable Carriers And Formulations | |
NO329486B1 (no) | Farmasoytiske sammensetninger omfattende vitamin D, et kortikosteroid og en opplosningsmiddelkomponent samt anvendelse derav | |
JP5079689B2 (ja) | 油性軟膏と可溶化された形態のビタミンdまたはその誘導体とを含む薬剤組成物 | |
US20110268665A1 (en) | Oil-based foamable carriers and formulations | |
IE904590A1 (en) | Stable cream and lotion bases for lipophilic drug¹compositions | |
JP2003525857A (ja) | エアゾール軟膏組成物および製造法 | |
US4233295A (en) | Corticosteroid formulations containing sebacate carrier | |
BR132017012408E2 (pt) | Composto, processo para a preparação de um composto, composições farmacêuticas tópicas estáveis de halobetasol | |
JP2006503026A (ja) | 局所施用のためのフェニルピリドン化合物の安定なクリーム製剤 | |
JPH0459292B2 (zh) | ||
WO2016170518A1 (en) | Pharmaceutical compositions comprising arformoterol and glycopyrronium | |
US20220110859A1 (en) | Composition and method for treating fungal skin conditions and inflammation | |
JPH02111717A (ja) | 安定化された徐放性エマルジヨン | |
JP5965187B2 (ja) | 油性軟膏剤 | |
US20060188449A1 (en) | Topical aerosol foams | |
TWI625130B (zh) | 凝膠基質及凝膠製劑 | |
CN117396196A (zh) | 局部萘普生制剂及其用途 | |
PL245212B1 (pl) | Oleożelowa kompozycja farmaceutyczna leku z grupy glikokortykosteroidów oraz jej zastosowanie w leczeniu schorzeń skórnych, stomatologicznych i ginekologicznych | |
JPH02178228A (ja) | 坐剤組成物 |